Cvs Health Corp CVS
We take great care to ensure that the data presented and summarized in this overview for CVS HEALTH Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVS
View all-
Vanguard Group Inc Valley Forge, PA116MShares$6.7 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY87.1MShares$5.02 Billion0.16% of portfolio
-
State Street Corp Boston, MA55MShares$3.17 Billion0.2% of portfolio
-
Capital World Investors Los Angeles, CA43.8MShares$2.53 Billion0.6% of portfolio
-
Dodge & Cox San Francisco, CA41MShares$2.37 Billion2.0% of portfolio
-
Capital International Investors Los Angeles, CA37.9MShares$2.19 Billion0.63% of portfolio
-
Morgan Stanley New York, NY29MShares$1.68 Billion0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA25.4MShares$1.46 Billion0.19% of portfolio
-
Bank Of America Corp Charlotte, NC16.2MShares$932 Million0.12% of portfolio
-
Invesco Ltd. Atlanta, GA14.6MShares$844 Million0.26% of portfolio
Latest Institutional Activity in CVS
Top Purchases
Top Sells
About CVS
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Insider Transactions at CVS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
J Scott Kirby Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,912
+34.08%
|
$165,984
$57.52 P/Share
|
May 16
2024
|
Michael F Mahoney Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+35.31%
|
$124,488
$57.52 P/Share
|
May 16
2024
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+50.0%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+1.87%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+6.78%
|
$131,898
$57.52 P/Share
|
May 16
2024
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,347
+6.37%
|
$133,779
$57.52 P/Share
|
May 16
2024
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,184
+23.08%
|
$124,488
$57.52 P/Share
|
May 02
2024
|
Michael F Mahoney Director |
BUY
Open market or private purchase
|
Direct |
9,181
+49.53%
|
$495,774
$54.49 P/Share
|
May 02
2024
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
1,000
+4.42%
|
$53,000
$53.88 P/Share
|
Apr 01
2024
|
J. David Joyner EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
28,280
+39.0%
|
-
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,426
+50.0%
|
$744,654
$79.56 P/Share
|
Apr 01
2024
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,630
-16.89%
|
$602,770
$79.56 P/Share
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,913
+22.61%
|
$546,127
$79.56 P/Share
|
Apr 01
2024
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,298
-8.88%
|
$181,542
$79.56 P/Share
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,683
+41.42%
|
$843,957
$79.56 P/Share
|
Apr 01
2024
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,004
-14.03%
|
$237,316
$79.56 P/Share
|
Apr 01
2024
|
Samrat S. Khichi EVP, CPO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+22.03%
|
-
|
Apr 01
2024
|
Brian A Kane EVP/President, Aetna |
BUY
Grant, award, or other acquisition
|
Direct |
12,569
+50.0%
|
-
|
Apr 01
2024
|
Tilak Mandadi EVP, Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,339
+16.46%
|
-
|
Apr 01
2024
|
Prem S Shah EVP and Pres-Pharm, Consumer W |
BUY
Grant, award, or other acquisition
|
Direct |
15,082
+28.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 381K shares |
---|---|
Open market or private purchase | 12.2K shares |
Payment of exercise price or tax liability | 122K shares |
---|---|
Open market or private sale | 55.2K shares |
Bona fide gift | 3.45K shares |